Tilray sets medical cannabis milestone in Italy
Tilray is a global consumer packaged goods company active in cannabis, beverage, wellness and entertainment
Tilray stock has given back 78.17 per cent year-over-year and 97.46 per cent since 2021
Tilray Medical, a division of major cannabis player Tilray Brands (TSX:TLRY), has become the first company to receive authorization from Italy's Ministero della Salute to distribute medical cannabis flower for therapeutic use.
Tilray Medical, operating through wholly-owned subsidiary, FL Group, will introduce three new medical cannabis flower varieties to Italy beginning in June, which will be available for distribution through pharmacies across the country. They are: Tilray THC 25%.
Tilray THC 18%.
Tilray THC 9% / CBD 9%.
The approval complements Tilray's existing presence in Italy, initially announced in May 2023, as well as its leading position in the European market, including operations in Germany, Portugal, Poland and the United Kingdom. Leadership insights
'This milestone underscores the vital role of medical cannabis as a therapeutic medicine for patients in need, supporting their health and well-being. We are proud to expand our medical cannabis portfolio in Italy with the introduction of our Tilray Medical high-quality, EU-GMP certified medical cannabis products that uphold the highest standards in patient care,' Denise Faltischek, Tilray Brands' chief strategy officer and head of international, said in a statement. 'We extend our gratitude to the Ministero della Salute for their trust in Tilray Medical and for providing the necessary regulatory framework to ensure access to safe, consistent and reliable cannabinoid-based therapies. Together, we are advancing healthcare and patient wellness through innovation and collaboration.' About Tilray Brands
Tilray is a global consumer packaged goods company active in cannabis, beverage, wellness and entertainment. The company's platform includes more than 40 brands spanning presences in more than 20 countries.
Tilray stock (TSX:TLRY) last traded at C$0.50. The stock has given back 78.17 per cent year-over-year and 97.46 per cent since 2021.
Join the discussion: Find out what investors are saying about this cannabis stock's expansion in Italy on the Tilray Brands Inc. Bullboard, and make sure to check out the rest of Stockhouse's stock forums and message boards.
The material provided in this podcast is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vancouver Sun
an hour ago
- Vancouver Sun
How Ukraine can cope with the U.S. pause on crucial battlefield weapons
The decision by the United States to pause some weapons shipments to Ukraine has come at a tough time for Kyiv: Russia's bigger army is making a concerted push on parts of the roughly 1,000-kilometer (620-mile) front line and is intensifying long-range drone and missile attacks that increasingly hammer civilians in Ukrainian cities. Washington has been Ukraine's biggest military backer since Russia launched a full-scale invasion of its neighbor on Feb. 24, 2022. But the Trump administration has been disengaging from the war, and no end to the fighting is in sight, despite recent direct peace talks. Here's a look at Ukraine's options following the U.S. pause of some arms deliveries: Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Amid recurring concerns in Kyiv about how much military support its allies can supply and how quickly, Ukraine has raced to build up its domestic defense industry. The country's output has gradually grown, especially in the production of more and increasingly sophisticated drones, but Ukraine needs to speedily scale up production. Crucially, some high-tech U.S. weapons are irreplaceable. They include Patriot air defense missiles, which are needed to fend off Russia's frequent ballistic missile attacks, but which cost $4 million each. That vital system is included in the pause, and many cities in Ukraine, including Kyiv, could become increasingly vulnerable. A senior Ukrainian official said Thursday that Patriot systems are 'critically necessary' for Ukraine, but U.S.-made HIMARS precision-guided missiles, also paused, are in less urgent need as other countries produce similar assets. 'Other countries that have these (Patriot) systems can only transfer them with U.S. approval. The real question now is how far the United States is willing to go in its reluctance to support Ukraine,' he told The Associated Press on condition of anonymity because of sensitivity of the subject. The official said that Patriot missiles exist in sufficient numbers globally, and he said that accessing them requires political resolve. 'There are enough missiles out there,' he said, without providing evidence. He also stated that Ukraine has already scaled up its domestic production of 155 mm artillery shells, which were once critically short, and is now capable of producing more than is currently contracted. 'Supplies from abroad have also become more available than before,' he said. Amid at times fraught relations with U.S. President Donald Trump, Ukrainian President Volodymyr Zelenskyy has been enlisting greater European help for his country's arms manufacturing plans. European countries don't have the production levels, military stockpiles or the technology to pick up all the slack left by the U.S. pause, but Zelenskyy is recruiting their help for ambitious joint investment projects. Draft legislation to help Ukrainian defense manufacturers scale up and modernize production, including building new facilities at home and abroad, will be put to a vote in the Ukrainian parliament later this month, Defense Minister Rustem Umerov announced this week. Zelenskyy said last month that major investments will go to the production of drones and artillery shells. 'The volume of support this year is the largest since the start of the full-scale war,' he said about commitments from foreign countries. Under Trump, there have been no new announcements of U.S. military or weapons aid to Ukraine. Between March and April, the United States allocated no new help at all, according to Germany's Kiel Institute, which tracks such support. For the first time since June 2022, four months after Russia's full-scale invasion, European countries have surpassed the U.S. in total military aid, totaling 72 billion euros ($85 billion) compared with 65 billion euros ($77 billion) from the U.S., the institute said last month. Without Patriot missiles, as well as the AIM-7 Sparrow air-to-air missile and shorter-range Stinger missiles that are also included in the pause, Ukrainian cities likely will take a bashing as more Russian missiles pierce air defenses. On the front line, Ukrainian troops haven't recently voiced complaints about ammunition shortages, as they have in the past. They have always said that during the war, they have never had as much ammunition to as their disposal as Russian forces. The army faces a different problem: It's desperately short-handed. It's turning to drones to compensate for its manpower shortage, and analysts say the front isn't about to collapse. Asked about the timing of the U.S. pause, the Ukrainian official emphasized the need for stable, reliable supply lines. 'This is war — and in war, steady deliveries are always crucial,' he said. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here .
Cision Canada
2 hours ago
- Cision Canada
Blue Sky Hemp Ventures Sells Hemp Food Division to Fresh Hemp Foods to Focus on Cannabis Extracts and Contract Manufacturing
SASKATOON, SK, July 3, 2025 /CNW/ - Blue Sky Hemp Ventures Ltd. ("Blue Sky"), a privately held Canadian company founded in 2017 and a pioneer in industrial hemp whole plant utilization, has sold its hemp-based food division to Fresh Hemp Foods, a major hemp food company, for an undisclosed amount. "Thanks to a differentiated strategy and disciplined execution, Blue Sky has delivered two consecutive years of positive EBITDA and net earnings—an uncommon achievement in this sector," said CEO Andrew Potter. "After strong growth in both our food and cannabis divisions, we reached a strategic crossroads. With limited physical space and capital, we concluded that monetizing our successful hemp food business would allow us to better scale our cannabis operations and drive long-term shareholder value." Proceeds from the sale will be used to accelerate expansion of Blue Sky's contract manufacturing services—including vape pens, pre-rolls, and softgels—building on its strong foundation in topicals and oils. The company is also on track to complete EU-GMP certification, unlocking new global opportunities for bulk extracts and finished products. "Although we had limited resources, our team successfully built a high-growth, EBITDA positive food business over the last few years. I'm incredibly proud of our product innovation, particularly our refined hemp seed oil—an excellent example of our ability to cost-effectively develop new products," said Potter. "This spirit of innovation will continue to drive our cannabis operations. We're confident the purchaser of our food operation will take this food business to the next level, and we look forward to supporting them." "We welcome Blue Sky's customers and suppliers to Fresh Hemp Foods. Blue Sky has championed whole plant utilization, and we intend to carry that forward alongside our own industry leading sustainability efforts. Fresh Hemp Foods remains focused on bringing nutritious, sustainable hemp foods to more and more customers and consumers," said Jared Simon, President, Manitoba Harvest and Tilray Wellness. About Blue Sky Hemp Ventures Founded in 2017, Blue Sky operates a 15,000 sq ft cannabis processing facility in Saskatoon, Saskatchewan. Following its latest expansion (completed December 2024), Blue Sky is one of the largest independent extractors in Canada, processing approximately 20,000 kg of dry cannabis flower per month. The company now operates two core divisions: Bulk Cannabinoid Extraction and Refinement Contract Manufacturing – including oils, topicals, and new offerings such as vapes, prerolls and softgels. Over the coming months, Blue Sky will continue to convert its facility to full EU-GMP compliance to support global manufacturing and extraction partnerships.
Winnipeg Free Press
3 hours ago
- Winnipeg Free Press
AGF Management says CEO Kevin McCreadie has died, Judy Goldring named successor
TORONTO – Investment firm AGF Management Ltd. says Kevin McCreadie, the firm's chief executive officer and chief investment officer, has died. He was 64. AGF executive chairman Blake Goldring says the company was devastated by the loss and that McCreadie's impact on the organization was profound and will be lasting. The company say McCreadie will be remembered for his passion for investment management and his focus on developing and nurturing talent for the future. AGF named Judy Goldring, AGF's president and head of global distribution, as CEO, effective immediately. Judy Goldring joined AGF in 1998 as general counsel and has held several roles with increasing responsibility across the firm. AGF has over $53 billion in total assets under management and fee-earning assets for more than 815,000 investors. Monday Mornings The latest local business news and a lookahead to the coming week. This report by The Canadian Press was first published July 3, 2025. Companies in this story: (TSX:AGF.B)
